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Patients with hypertension often show evidence of 
insulin resistance, and up to 75% of adults with diabetes 
also have hypertension1. Many factors can increase the 
risk of hypertension, one of which is diabetes mellitus 
(DM)2. Peripheral artery resistance and body fluid 
volume increase in DM patients, both of these 
mechanisms can increase blood pressure3. 
Type 2 diabetes mellitus (T2DM) is associated with a high 
risk of mortality in hypertension patients4. Hypertension 
treatment aims to reduce mortality and morbidity, where 
drug selection is essential in therapy success5. Some 
references show that the potential for drug-related 
problems increases in patients with chronic diseases, 
including T2DM6,7. 
Our previous research has found that T2DM is a 
common comorbid disease in hypertension patients8. 
However, there is no research on drug-related problems 
in hypertension with comorbid T2DM patients at 
Primary Health Care Center at Batununggal District, 
Bandung. Therefore, researchers are interested in 
researching drug-related problems in hypertension with 
comorbid T2DM patients, which has never been done 
before. This research aimed to find whether there are 
drug-related problems in hypertension with comorbid 
T2DM patients, providing information for other health 
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 Abstract 
Many factors can increase the risk of hypertension, one of which is 
diabetes mellitus. The study aims to provide an overview of Drug-
Related Problems (DRPs) in patients with hypertension comorbid type 
2 diabetes mellitus at Primary Health Care Center Batununggal 
District Bandung. This research was an observational study with 
retrospective data collection and descriptive analysis. Data were taken 
from patient prescriptions January-December 2019 period. The sample 
inclusion criteria are patients aged 30-75 years, patients diagnosed 
with hypertension comorbid type 2 diabetes mellitus, and patients 
treated in January-December 2019. The number of samples that met 
the inclusion criteria was 268 patients, of which 69 patients (25.75%) 
are male, and 199 patients (74.25%) are female. 164 patients (61.2%) are 
aged 60-75 years old. It is found that 1 case (0.37%) has the drug-
related problem of drug overdose and as many as 34 cases (12.69%) 
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professionals to improve patients' service and achieve 
treatment targets. 
 
MATERIALS AND METHODS 
Materials 
The tool for data collection was a laptop, and the 
materials used were a prescription sheet of hypertension 
with comorbid T2DM patients, references, i.e., research 
journals, and textbook (Pharmacotherapy: A 
Pathophysiology Approach)9. The data for the study was 
taken from a prescription sheet. Data collected included 
patient name (initials), gender, age, diagnosis, drugs data 
(name, dosage strength, dosage form, quantity, and 
frequency of use). A prescription sheet of hypertension 
comorbid T2DM patients between January and 
December 2019 was obtained with a total of 303 samples. 
Methods 
The research conducted was an observational study with 
retrospective data collection and descriptive analysis. The 
aim was to identify any drug-related problems in 
hypertension with comorbid T2DM patients at Primary 
Health Care Center Batununggal District Bandung. The 
samples taken were adjusted to the inclusion and 
exclusion criteria that had been set. Inclusion criteria: 
Patients aged 30-75 years, Patients diagnosed with 
hypertension with comorbid T2DM, and patients treated 
in January-December 2019. Exclusion criteria: Patients 
who were pregnant or breastfeeding and patients with 
an incomplete prescription. Data that met the inclusion 
criteria were taken and analyzed quantitatively (number 
of patients based on gender, age, and diagnosis; data of 
drug use; percentage of drug-related problems case) and 
qualitatively (analysis of drug-related problems). This 
study has received ethical approval from The Health 
Research Ethics Committee of the Faculty of Medicine of 
Universitas Jenderal Achmad Yani with reference 
number 032/UM4.10/2020. 
RESULTS AND DISCUSSION 
The research was conducted at Primary Health Care 
Center at Batununggal District Bandung. Data used in 
this research were from January to December 2019, with 
the number of samples obtained as many as 268 met 
inclusion criteria. The samples used were patients with a 
diagnose of hypertension with comorbid T2DM 
according to the inclusion criteria. 
Table I showed that from 268 patients, 69 patients 
(25.75%) were male, and 199 patients (74.25%) were 
female. These results were in line with the previous 
research conducted at the same Primary Health Care 
Center in 2019, in which the most treated patients were 
female patients. Likewise, the result of Riset Kesehatan 
Dasar (Riskesdas) 201810, the percentage of hypertension 
prevalence in female patients was higher than in male 
patients. The incidence of hypertension is higher in 
women because in the menopause phase, there is a 
hormonal imbalance, which is a decrease in the ratio of 
estrogen and androgen, which causes an increase in the 
release of renin, which will lead to an increase in blood 
pressure11. Apart from gender, age also affects the 
incidence of hypertension, the age range 55-90 years has 
a four times higher risk than those aged 18-54 years12. 
The patients taken were at least 30 years old because, 
from previous research8, patients admitted to Primary 
Health Care Center at Batununggal District Bandung 
were at least 30 years old. In this study, patients aged 60-
75 years (61.20%) had the most hypertension due to 
increasing age, structural and functional changes that 
caused the arteries to lose their flexibility. When the 
flexibility decreases, the blood vessels become stiff; 
therefore, the blood with each heartbeat is forced through 
the narrow blood vessels, increasing blood pressure13. 
Factors like gender, smoking, alcohol consumption, 
overweight, and obesity also were associated with 
hypertension, diabetes, and dyslipidemia14. 
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The majority of hypertension with comorbid T2DM 
patients suffer from other comorbidities. Due to this 
multi-diagnosis condition, the patient takes a wide range 
of drugs and increases the risk of drug-related 
problems15. Another comorbidity with the highest 
percentage in hypertension with comorbid T2DM 
patients was hyperlipidemia (31.34%). 
Table I. Characteristics of hypertension patients with 
comorbid T2DM at Primary Health Care Center at 







Male 69 25.75 
Female 199 74.25 
Total 268 100 
Age (year) 
30-44 4 1.49 
45-59 100 37.31 
60-75 164 61.20 
Total 268 100 
Diagnose 
Hypertension + T2DM 86 32.09 
Hypertension + T2DM + Other 
Comorbidities 
182 67.91 
Total 268 100 
Other comorbidities 
Hyperlipidemia 84 31.34 
Hyperuricemia 23 8.58 






Skin and Subcutaneous Tissue 
Diseases 
13 4.85 
Respiratory System Diseases 10 3.73 
Infectious Diseases 6 2.24 
Gastrointestinal Diseases 5 1.87 
Circulatory System Diseases 4 1.49 




Psychiatric Diseases 1 0.37 
Others (Hemoptysis; Cough; 
Other chest pain; Fever, 
unspecified; Headache; 
Localized edema; Obesity; 
Superficial injury of shoulder 
and upper arm; Disorders of 
vestibular function) 
20 7.46 
Total 268 100 
 
Tables II and III showed data on antihypertension and 
antidiabetic use. All hypertension with comorbid T2DM 
patients uses antihypertension and antidiabetic drugs by 
the oral route of administration, either single or in 
combination. In addition, hypertension with comorbid 
T2DM patients with other comorbidities also receives 
medication according to the patient's diagnosis. 
Table II. Data of antihypertension used in patients with 
comorbid T2DM at Primary Health Care Center at 
Batununggal District Bandung 
Drug Name 







Amlodipine Oral 264 98.51 
Amlodipine 
+ Captopril 
Oral 4 1.49 
Total 268 100 
 
Table III. Data of antidiabetic used in patients with comorbid 
T2DM at Primary Health Care Center at 
Batununggal District Bandung 
Drug Name 







Metformin Oral 240 89.55 
Glimepiride Oral 1 0.37 
Metformin + 
Glimepiride 
Oral 18 6.72 
Metformin + 
Glibenclamide 
Oral 9 3.36 
Total 268 100 
 
Table IV showed data of drug uses based on drug class. 
Besides antihypertension and antidiabetic drugs that 
were often used, from 268 patients, there was 170 use of 
vitamins: B1, B6, B12, or B complex. Vitamin B complex, 
B12, and B1 were widely used as supporting vitamins in 
reducing blood pressure and cholesterol levels. Vitamin 
B12 is prescribed to reduce complaints of aches suffered 
by patients and meet vitamin intake to avoid vitamin B12 
deficiency16. Vitamin B12 deficiency can increase 
homocysteine levels, where high homocysteine levels 
can increase the risk of increased blood pressure through 
decreased availability of nitric oxide, thereby interfering 
with vascular vasodilation. Hyperhomocysteinemia can 
also damage the endothelium and cause atherosclerosis; 
therefore, vitamin B12 needs to be added17,18. 
In hypertension with comorbid T2DM patients, 
pharmacists can also provide advice on non-
pharmacological therapies such as lifestyle modification. 
Besides lowering blood pressure in patients with 
hypertension, lifestyle modification can also reduce 
blood pressure progression to hypertension in patients 
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with prehypertension blood pressure19. A vital lifestyle 
modification that appears to lower blood pressure is 
weight loss for obese or obese individuals; adopt the 
DASH (Dietary Approach to Stop Hypertension) diet 
rich in potassium and calcium; low sodium diet; physical 
activity; and consume only a little alcohol. In several 
patients with reasonable blood pressure control with 
single antihypertensive drug therapy, reducing salt and 
weight can relieve patients from using the drugs20. 
Lifestyle modification alone is an appropriate therapy for 
patients with prehypertension. Patients diagnosed with 
stage 1 or 2 hypertension should be placed on concurrent 
lifestyle modification and drug therapy21. 
Table IV. Data of drug used based on drug class in patients 
with comorbid T2DM at Primary Health Care 
Center at Batununggal District Bandung 
Drug Class 







Antidiabetic Oral 295 27.16 
Antihypertension Oral 272 25.05 
Vitamin Oral 170 15.65 
Antihyperlipidemia Oral 79 7.27 
Analgesics 
Antipyretic 
Oral 68 6.26 
NSAID Oral 34 3.13 
Antihistamine Oral 30 2.76 
Antihyperuricemia Oral 24 2.21 
Cough medicine Oral 23 2.12 
Calcium Lactate Oral 23 2.12 
Antacids Oral 17 1.57 
H2 Receptor 
Antagonist 
Oral 7 0.64 
Proton Pump 
Inhibitor 
Oral 7 0.64 
Antibiotics Oral 5 0.46 
Potent Diuretic Oral 4 0.37 
Antivertigo Oral 4 0.37 
Antidiarrheal Oral 4 0.37 
Antiemesis Oral 3 0.28 
Laksative Oral 1 0.09 
Antifungi Topical 6 0.55 
Corticosteroids Topical 3 0.28 
Antibiotics Topical 3 0.28 
Antibiotics Ocular 4 0.37 
Total Usage 1086 100 
 
Figure 1 shows the percentage of drug-related problems 
cases in patients with comorbid T2DM at Primary Health 
Care Center at Batununggal District Bandung. Problems 
related to the drugs analyzed were improper drug 
selection, overdose, subdose, and drug interactions. 
There are no cases of improper drug selection because 
patients received drugs according to therapy guidelines 
and drugs available at Primary Health Care Center at 
Batununggal District Bandung. There are also no cases of 
subdose. Based on the analysis results, it was found that 
1 case (0.37%) out of 268 patients experienced problems 
related to drug overdose, in which the patient received 
amlodipine 15 mg/day. The maximum dose of 
amlodipine is 10 mg /day22. 
 
Figure 1. Percentage of drug-related problems cases in patients 
with comorbid T2DM at Primary Health Care Center at 
Batununggal District Bandung 
 
In addition to overdoses, a potential drug-related 
problem is drug interactions. Figure 1 showed that 34 
cases (12.69%) out of 268 patients have potential drug 
interactions. Based on the analysis results in Table V, 
there was an interaction between amlodipine and non-
steroidal anti-inflammatory drugs like diclofenac sodium 
and mefenamic acid. Non-steroidal anti-inflammatory 
drugs can increase blood pressure and reduce the 
hypotensive effect of antihypertension23,24. These results 
can be considered so that the drug administration service 
to patients also provides suggestions for monitoring 
blood pressure. Home blood pressure monitoring 
(HBPM) is a self-monitoring tool recommended for 
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Table V. Potential drug interactions in patients with 
comorbid T2DM at Primary Health Care Center at 
Batununggal District Bandung 
Drug 
Interactions 






































The results in this study show a slight variation 
compared to other similar studies conducted in other 
locations. Other research results showed that drug-
related problems with the highest prevalence in clinical 
practice were caused by drug or dose selection26. Another 
study in patients with hypertension showed that the 
most identified drug-related problem was drug 
interactions27. At the same time, other research showed 
that the most common drug-related problems that 
occurred in T2DM with hypertension were insufficient 
awareness of health and diseases (26%), drug choice 
problems (23%), dosing problems (16%), and drug 
interactions (16%)28. Differences in research locations are 
important factors related to the types of drug-related 
problems encountered, especially for hypertensive 
patients with comorbid T2DM. 
 
CONCLUSION 
In the January-December 2019 period at Primary Health 
Care Center Batununggal District Bandung, drug-related 
problems on hypertension with comorbid T2DM 
patients were overdose and potential drug interactions. 
The pharmacist's role is needed in identifying drug-
related problems and being able to communicate these 
problems with other health professionals. It is 
recommended to carry out further research at the same 
health center or other health centers in order to obtain a 
more comprehensive conclusion. 
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